Blepharitis is a common eye condition characterized by chronic inflammation of the eyelids which can lead to redness, scaling, and crusting of the eyelid margins. It is usually caused by hypersecretion of Meibomian glands, contact lens use, or Demodex, a type of tiny mite that lives on the human eyelashes. Blepharitis affects around 25% of the population and leads to symptoms such as itchy, burning eyes, eye irritation, dry eyes, red eyelids, and in severe cases can also cause blurred vision. Effective treatment of blepharitis is needed to reduce symptoms and prevent further complications.
The global blepharitis treatment market is estimated to be valued at US$ 2.5 Bn in 2024 and is expected to exhibit a CAGR of 10% over the forecast period 2023 to 2030.
Growing geriatric population prone to blepharitis and increased awareness regarding eye diseases are major factors driving the market. Additionally, technological advancements in novel therapeutics and eye care devices for treatment of blepharitis are further fueling the market growth.
Key Takeaways
Key players operating in the blepharitis treatment market are Scope Ophthalmic Ltd., NovaBay Pharmaceuticals Inc., Thea Pharmaceuticals Ltd., Perrigo Laboratories, InSite Vision Incorporated, Merck & Co., and Novartis AG. These players are focusing on expanding their product portfolios through acquisitions and new product launches.
The increasing awareness regarding eye health and rising cases of digital eye strain offer significant growth opportunities in the blepharitis treatment market. Novel therapeutics and digital eye care devices present lucrative prospects.
Geographically, North America dominated the global market in 2023 due to high healthcare spending and growing geriatric population. However, Asia Pacific is expected to exhibit fastest growth over the forecast period supported by improving healthcare infrastructure and rising medical tourism in the region.
Market Drivers
Increasing geriatric population- The prevalence of blepharitis increases with age and people over 60 years have higher risk. According to the United Nations, the geriatric population is expected grow dramatically between 2023-2050 which will boost demand for effective blepharitis treatments.
Technological advancements- Major players are developing novel drugs, eye devices and artificial intelligence-based technologies for precise evaluation and treatment of blepharitis. This is positively impacting the market growth.
Market Restrain
High cost of advanced treatments- Novel drugs, digital devices and surgical procedures for blepharitis management involve high costs which may limit their adoption in price sensitive markets. This acts as a major restraint for market growth.
Segment Analysis
The blepharitis treatment market is dominated by the over-the-counter (OTC) sub segment. This sub segment accounts for nearly 70% of the total market share as majority of blepharitis cases are mild in nature and can be treated with OTC drugs. OTC drugs for blepharitis treatment such as artificial tears, eyelid cleansers/scrubs, topical antibiotics are easily available and offer convenience of use to patients. Their greater affordability as compared to prescription drugs also contributes to the high demand for OTC blepharitis treatment options.
The prescription drugs sub segment is the next major segment in this market. This segment is estimated to grow at a faster pace during the forecast period attributed to the increasing prevalence of chronic and severe forms of blepharitis that require prescription medication such as antibiotics, steroids and other eye drops.
Global Analysis
North America dominates the global blepharitis treatment market and is expected to continue its dominance during the forecast period. This is attributed to high awareness regarding blepharitis, strong healthcare infrastructure and greater emphasis on eye care. The growth in the North America region will be further fueled by new product launches, increasing healthcare expenditure and presence of major market players.
On the other hand, Asia Pacific region will witness the highest growth rate during the forecast period owing to rapidly developing healthcare facilities, rising medical tourism, increasing discretionary incomes and growing eye disease burden. Initiatives aimed at raising awareness about eye disorders like blepharitis among general population will further support market growth in Asia Pacific.
No comments:
Post a Comment